[Use of dibunol in treating radiation injuries to the skin and mucosa].
The authors present the results of the use of dibunol in the form of liniment (1-10%) for the treatment of radiation cystitis and rectitis resulting from radiation therapy of small pelvic tumors, epidermitis and epithelitis that develop in the course of treatment of skin and lower lip tumors. A high efficacy of the drug in the therapy of radiation injury has been shown in 212 patients.
D000368:Aged; D002084:Butylated Hydroxytoluene / Q000627:therapeutic use*; D003556:Cystitis / Q000188:drug therapy / Q000209:etiology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008048:Lip Neoplasms / Q000150:complications / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000528:radiation effects*; D010386:Pelvic Neoplasms / Q000150:complications / Q000532:radiotherapy; D011349:Proctitis / Q000188:drug therapy / Q000209:etiology; D011855:Radiodermatitis / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000150:complications / Q000532:radiotherapy
D002084:Butylated Hydroxytoluene
Primenenie dibunola pri lechenii luchevykh povrezhdeniĭ kozhi i slizistykh obolochek.